CIB Just Beat Earnings by 55% and Nobody's Talking About It

Signal: BUY | Score: 68.16/100

Bancolombia's ADR is sitting just below its 52-week high after a blowout quarter, a Goldman Sachs upgrade, and a major product launch on the horizon. The stock doubled off its lows, fundamentals are pristine, and momentum is building. This is a trend continuation play with real earnings power behind it.

The Setup

CIB is trading at $98.66, just 2% below its 52-week high of $100.74 after more than doubling from the $49.11 low set earlier in the year. RSI is at 70, which sounds extended, but when a stock is breaking out on fundamentals this strong, overbought readings often stay overbought. The momentum score of 72 confirms the trend is intact. The technical score of 60 suggests this isn't a runaway euphoria trade - it's a measured, fundamentals-driven grind higher with room to extend.

The Catalyst

Three things hit in rapid succession and the market still hasn't fully priced them in.

On August 10, CIB reported Q2 2026 EPS of $3.32 against a consensus estimate of $2.14 - a 55% beat. Net income grew 29% year over year in the quarter, and 18% for the first half of 2026. That kind of bottom-line acceleration in a regional bank is rare.

On July 31, management announced the September launch of Nequi financing, an independent digital lending arm tied to their fast-growing fintech platform. This is a new revenue stream that analysts haven't had time to model properly yet.

And on July 28, Goldman Sachs upgraded CIB to Buy. When Goldman moves on a regional emerging market bank, institutional money follows.

Bull Case

Earnings momentum is real. Full-year 2025 net income grew 49% year over year, and 2026 is tracking even faster. The forward P/E of 8.6x and PEG ratio of 0.43 mean you're buying genuine growth at a discount.
Nequi financing is a free option. The market isn't pricing in a successful fintech lending launch. If September goes well, analysts revise targets higher and shares break through $100 cleanly.
You get paid to wait. A 4% dividend yield cushions any short-term volatility while the thesis plays out.

Bear Case

The average analyst target is $82.63, well below the current price. Consensus is lagging the earnings acceleration, but that gap is a risk if the upgrade cycle stalls.
Beta of 0.44 keeps big moves limited - don't expect a moonshot. This is a compounder, not a momentum lottery ticket.

The Trade

Entry: $98.66
Target: $112.00 (roughly 13% upside, pricing in Nequi launch success)
Stop Loss: $91.00 (just below the pre-earnings consolidation zone)
Risk/Reward: approximately 2:1
Timeframe: 60 to 90 days, with next earnings on November 9

*This is one person's analysis, not financial advice. Always do your own research.*